|
1
|
Nicholson MK, Ghazal Asswad R and Wilding
JP: Dapagliflozin for the treatment of type 2 diabetes mellitus-an
update. Expert Opin Pharmacother. 22:2303–2310. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
González-Muniesa P, Mártinez-González MA,
Hu FB, Després JP, Matsuzawa Y, Loos RJF, Moreno LA, Bray GA and
Martinez JA: Obesity. Nat Rev Dis Primers. 3(17034)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Iglay K, Hannachi H, Joseph Howie P, Xu J,
Li X, Engel SS, Moore LM and Rajpathak S: Prevalence and
co-prevalence of comorbidities among patients with type 2 diabetes
mellitus. Curr Med Res Opin. 32:1243–1252. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Einarson TR, Acs A, Ludwig C and Panton
UH: Prevalence of cardiovascular disease in type 2 diabetes: A
systematic literature review of scientific evidence from across the
world in 2007-2017. Cardiovasc Diabetol. 17(83)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
American Diabetes Association. 8. Obesity
management for the treatment of type 2 diabetes: Standards of
medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S89–S97.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Uneda K, Kawai Y, Yamada T, Kinguchi S,
Azushima K, Kanaoka T, Toya Y, Wakui H and Tamura K: Systematic
review and meta-analysis for prevention of cardiovascular
complications using GLP-1 receptor agonists and SGLT-2 inhibitors
in obese diabetic patients. Sci Rep. 11(10166)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Feng M, Lv H, Xu X, Wang J, Lyu W and Fu
S: Efficacy and safety of dapagliflozin as monotherapy in patients
with type 2 diabetes mellitus: A meta-analysis of randomized
controlled trials. Medicine (Baltimore). 98(e16575)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aso Y, Kato K, Sakurai S, Kishi H, Shimizu
M, Jojima T, Iijima T, Maejima Y, Shimomura K and Usui I: Impact of
dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble
dipeptidyl peptidase-4 in patients with type 2 diabetes and
non-alcoholic fatty liver disease. Int J Clin Pract.
73(e13335)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bailey CJ, Gross JL, Hennicken D, Iqbal N,
Mansfield TA and List JF: Dapagliflozin add-on to metformin in type
2 diabetes inadequately controlled with metformin: A randomized,
double-blind, placebo-controlled 102-week trial. BMC Med.
11(43)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cefalu WT, Leiter LA, de Bruin TW,
Gause-Nilsson I, Sugg J and Parikh SJ: Dapagliflozin's effects on
glycemia and cardiovascular risk factors in high-risk patients with
type 2 diabetes: A 24-week, multicenter, randomized, double-blind,
placebo-controlled study with a 28-week extension. Diabetes Care.
38:1218–1227. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Grandy S, Hashemi M, Langkilde AM, Parikh
S and Sjöström CD: Changes in weight loss-related quality of life
among type 2 diabetes mellitus patients treated with dapagliflozin.
Diabetes Obes Metab. 16:645–650. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Henry RR, Murray AV, Marmolejo MH,
Hennicken D, Ptaszynska A and List JF: Dapagliflozin, metformin XR,
or both: Initial pharmacotherapy for type 2 diabetes, a randomised
controlled trial. Int J Clin Pract. 66:446–456. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Iacobellis G and Gra-Menendez S: Effects
of dapagliflozin on epicardial fat thickness in patients with type
2 diabetes and obesity. Obesity (Silver Spring). 28:1068–1074.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ji L, Ma J, Li H, Mansfield TA, T'joen CL,
Iqbal N, Ptaszynska A and List JF: Dapagliflozin as monotherapy in
drug-naive Asian patients with type 2 diabetes mellitus: A
randomized, blinded, prospective phase III study. Clin Ther.
36:84–100.e9. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kaku K, Kiyosue A, Inoue S, Ueda N,
Tokudome T, Yang J and Langkilde AM: Efficacy and safety of
dapagliflozin monotherapy in Japanese patients with type 2 diabetes
inadequately controlled by diet and exercise. Diabetes Obes Metab.
16:1102–1110. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kohan DE, Fioretto P, Tang W and List JF:
Long-term study of patients with type 2 diabetes and moderate renal
impairment shows that dapagliflozin reduces weight and blood
pressure but does not improve glycemic control. Kidney Int.
85:962–971. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lambers Heerspink HJ, de Zeeuw D, Wie L,
Leslie B and List J: Dapagliflozin a glucose-regulating drug with
diuretic properties in subjects with type 2 diabetes. Diabetes Obes
Metab. 15:853–862. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Leiter LA, Cefalu WT, de Bruin TWA,
Gause-Nilsson I, Sugg J and Parikh SJ: Dapagliflozin added to usual
care in individuals with type 2 diabetes mellitus with preexisting
cardiovascular disease: A 24-week, multicenter, randomized,
double-blind, placebo-controlled study with a 28-week extension. J
Am Geriatr Soc. 62:1252–1262. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
List JF, Woo V, Morales E, Tang W and
Fiedorek FT: Sodium-glucose cotransport inhibition with
dapagliflozin in type 2 diabetes. Diabetes Care. 32:650–657.
2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mathieu C, Ranetti AE, Li D, Ekholm E,
Cook W, Hirshberg B, Chen H, Hansen L and Iqbal N: Randomized,
double-blind, phase 3 trial of triple therapy with dapagliflozin
add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes
Care. 38:2009–2017. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Matthaei S, Bowering K, Rohwedder K, Sugg
J, Parikh S and Johnsson E: Study 05 Group. Durability and
tolerability of dapagliflozin over 52 weeks as add-on to metformin
and sulphonylurea in type 2 diabetes. Diabetes Obes Metab.
17:1075–1084. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rosenstock J, Hansen L, Zee P, Li Y, Cook
W, Hirshberg B and Iqbal N: Dual add-on therapy in type 2 diabetes
poorly controlled with metformin monotherapy: A randomized
double-blind trial of saxagliptin plus dapagliflozin addition
versus single addition of saxagliptin or dapagliflozin to
metformin. Diabetes Care. 38:376–383. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rosenstock J, Vico M, Wei L, Salsali A and
List JF: Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c),
body weight, and hypoglycemia risk in patients with type 2 diabetes
inadequately controlled on pioglitazone monotherapy. Diabetes Care.
35:1473–1478. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schumm-Draeger PM, Burgess L, Korányi L,
Hruba V, Hamer-Maansson JE and de Bruin TW: Twice-daily
dapagliflozin co-administered with metformin in type 2 diabetes: A
16-week randomized, placebo-controlled clinical trial. Diabetes
Obes Metab. 17:42–51. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Strojek K, Yoon KH, Hruba V, Elze M,
Langkilde AM and Parikh S: Effect of dapagliflozin in patients with
type 2 diabetes who have inadequate glycaemic control with
glimepiride: A randomized, 24-week, double-blind,
placebo-controlled trial. Diabetes Obes Metab. 13:928–938.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wilding JPH, Norwood P, T'Joen C, Bastien
A, List JF and Fiedorek FT: A study of dapagliflozin in patients
with type 2 diabetes receiving high doses of insulin plus insulin
sensitizers: Applicability of a novel insulin-independent
treatment. Diabetes Care. 32:1656–1662. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wilding JPH, Woo V, Rohwedder K, Sugg J
and Parikh S: Dapagliflozin 006 Study Group. Dapagliflozin in
patients with type 2 diabetes receiving high doses of insulin:
Efficacy and safety over 2 years. Diabetes Obes Metab. 16:124–136.
2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yamakage H, Tanaka M, Inoue T, Odori S,
Kusakabe T and Satoh-Asahara N: Effects of dapagliflozin on the
serum levels of fibroblast growth factor 21 and myokines and muscle
mass in Japanese patients with type 2 diabetes: A randomized,
controlled trial. J Diabetes Investig. 11:653–661. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yang W, Han P, Min KW, Wang B, Mansfield
T, T'Joen C, Iqbal N, Johnsson E and Ptaszynska A: Efficacy and
safety of dapagliflozin in Asian patients with type 2 diabetes
after metformin failure: A randomized controlled trial. J Diabetes.
8:796–808. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH,
Zhao J and Ptaszynska A: Dapagliflozin as add-on therapy in Asian
patients with type 2 diabetes inadequately controlled on insulin
with or without oral antihyperglycemic drugs: A randomized
controlled trial. J Diabetes. 10:589–599. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang L, Feng Y, List J, Kasichayanula S
and Pfister M: Dapagliflozin treatment in patients with different
stages of type 2 diabetes mellitus: Effects on glycaemic control
and body weight. Diabetes Obes Metab. 12:510–516. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang DD, Mao YZ, He SM and Chen X:
Analysis of time course and dose effect from metformin on body mass
index in children and adolescents. Front Pharmacol.
12(611480)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen X, Wang DD and Li ZP: Time course and
dose effect of metformin on weight in patients with different
disease states. Expert Rev Clin Pharmacol. 13:1169–1177.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen X, Wang DD and Li ZP: Analysis of
time course and dose effect of tacrolimus on proteinuria in lupus
nephritis patients. J Clin Pharm Ther. 46:106–113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang DD, Li YF, Mao YZ, He SM, Zhu P and
Wei QL: A machine-learning approach for predicting the effect of
carnitine supplementation on body weight in patients with
polycystic ovary syndrome. Front Nutr. 9(851275)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
DeFronzo RA, Hompesch M, Kasichayanula S,
Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching
A, et al: Characterization of renal glucose reabsorption in
response to dapagliflozin in healthy subjects and subjects with
type 2 diabetes. Diabetes Care. 36:3169–3176. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gerich JE: Role of the kidney in normal
glucose homeostasis and in the hyperglycaemia of diabetes mellitus:
therapeutic implications. Diabet Med. 27:136–142. 2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vallon V, Platt KA, Cunard R, Schroth J,
Whaley J, Thomson SC, Koepsell H and Rieg T: SGLT2 mediates glucose
reabsorption in the early proximal tubule. J Am Soc Nephrol.
22:104–112. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kaku K, Maegawa H, Tanizawa Y, Kiyosue A,
Ide Y, Tokudome T, Hoshino Y, Yang J and Langkilde AM:
Dapagliflozin as monotherapy or combination therapy in Japanese
patients with type 2 diabetes: An open-label study. Diabetes Ther.
5:415–433. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang M, Zhang L, Wu B, Song H, An Z and
Li S: Dapagliflozin treatment for type 2 diabetes: A systematic
review and meta-analysis of randomized controlled trials. Diabetes
Metab Res Rev. 30:204–221. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Vallon V and Thomson SC: Targeting renal
glucose reabsorption to treat hyperglycaemia: The pleiotropic
effects of SGLT2 inhibition. Diabetologia. 60:215–225.
2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wilson C: Diabetes: Dapagliflozin: An
insulin-independent, therapeutic option for type 2 diabetes
mellitus. Nat Rev Endocrinol. 6(531)2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Gilor C, Niessen SJM, Furrow E and
DiBartola SP: What's in a name? Classification of diabetes mellitus
in veterinary medicine and why it matters. J Vet Intern Med.
30:927–940. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Fioretto P, Mansfield TA, Ptaszynska A,
Yavin Y, Johnsson E and Parikh S: Long-term safety of dapagliflozin
in older patients with type 2 diabetes mellitus: A pooled analysis
of phase IIb/III studies. Drugs Aging. 33:511–522. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Durán-Martínez M, Azriel S,
Doulatram-Gamgaram VK, Moreno-Pérez Ó, Pinés-Corrales PJ,
Tejera-Pérez C, Merino-Torres JF, Brito-Sanfiel M, Chico A, Marco
A, et al: Real-world safety and effectiveness of dapagliflozin in
people living with type 1 diabetes in Spain: The Dapa-ON
multicenter retrospective study. Diabetes Metab.
50(101501)2024.PubMed/NCBI View Article : Google Scholar
|
